This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDowell, J. A.
Right arrow Articles by Stein, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDowell, J. A.
Right arrow Articles by Stein, D. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1999, p. 2855-2861, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pharmacokinetics of [14C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study

James A. McDowell,1,* Gregory E. Chittick,1 Joshua R. Ravitch,1 Ronald E. Polk,2 Thomas M. Kerkering,2 and Daniel S. Stein1

Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709,1 and Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia 232192

Received 5 March 1999/Returned for modification 22 June 1999/Accepted 8 September 1999

Abacavir (1592U89) {(-)-(1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol} is a 2'-deoxyguanosine analogue with potent activity against human immunodeficiency virus (HIV) type 1. To determine the metabolic profile, routes of elimination, and total recovery of abacavir and metabolites in humans, we undertook a phase I mass balance study in which six HIV-infected male volunteers ingested a single 600-mg oral dose of abacavir including 100 µCi of [14C]abacavir. The metabolic disposition of the drug was determined through analyses of whole-blood, plasma, urine, and stool samples, collected for a period of up to 10 days postdosing, and of cerebrospinal fluid (CSF), collected up to 6 h postdosing. The radioactivity from abacavir and its two major metabolites, a 5'-carboxylate (2269W93) and a 5'-glucuronide (361W94), accounted for the majority (92%) of radioactivity detected in plasma. Virtually all of the administered dose of radioactivity (99%) was recovered, with 83% eliminated in urine and 16% eliminated in feces. Of the 83% radioactivity dose eliminated in the urine, 36% was identified as 361W94, 30% was identified as 2269W93, and 1.2% was identified as abacavir; the remaining 15.8% was attributed to numerous trace metabolites, of which <1% of the administered radioactivity was 1144U88, a minor metabolite. The peak concentration of abacavir in CSF ranged from 0.6 to 1.4 µg/ml, which is 8 to 20 times the mean 50% inhibitory concentration for HIV clinical isolates in vitro (0.07 µg/ml). In conclusion, the main route of elimination for oral abacavir in humans is metabolism, with <2% of a dose recovered in urine as unchanged drug. The main route of metabolite excretion is renal, with 83% of a dose recovered in urine. Two major metabolites, the 5'-carboxylate and the 5'-glucuronide, were identified in urine and, combined, accounted for 66% of the dose. Abacavir showed significant penetration into CSF.

* Corresponding author. Mailing address: Worldwide Clinical Pharmacology, Glaxo Wellcome, Inc., Five Moore Dr., Research Triangle Park, NC 27709. Phone: (919) 483-1102. Fax: (919) 483-6380. E-mail: JAM36914{at}glaxowellcome.com.

Antimicrobial Agents and Chemotherapy, December 1999, p. 2855-2861, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Shaik, N., Giri, N., Pan, G., Elmquist, W. F. (2007). P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution. Drug Metab. Dispos. 35: 2076-2085 [Abstract] [Full Text]  
  • Pan, G., Giri, N., Elmquist, W. F. (2007). Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine. Drug Metab. Dispos. 35: 1165-1173 [Abstract] [Full Text]  
  • Goedken, A. M, Herman, R. A (2005). Once-Daily Abacavir in Place of Twice-Daily Administration. The Annals of Pharmacotherapy 39: 1302-1308 [Abstract] [Full Text]  
  • Capparelli, E. V., Letendre, S. L., Ellis, R. J., Patel, P., Holland, D., McCutchan, J. A. (2005). Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid. Antimicrob. Agents Chemother. 49: 2504-2506 [Abstract] [Full Text]  
  • DiCenzo, R., Forrest, A., Squires, K. E., Hammer, S. M., Fischl, M. A., Wu, H., Cha, R., Morse, G. D. (2003). Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects. Antimicrob. Agents Chemother. 47: 1929-1935 [Abstract] [Full Text]  
  • De Luca, A., Ciancio, B. C., Larussa, D., Murri, R., Cingolani, A., Rizzo, M. G., Giancola, M. L., Ammassari, A., Ortona, L. (2002). Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 59: 342-347 [Abstract] [Full Text]  
  • Thomas, S. A., Bye, A., Segal, M. B. (2001). Transport Characteristics of the Anti-human Immunodeficiency Virus Nucleoside Analog, Abacavir, into Brain and Cerebrospinal Fluid. J. Pharmacol. Exp. Ther. 298: 947-953 [Abstract] [Full Text]  
  • Weller, S., Radomski, K. M., Lou, Y., Stein, D. S. (2000). Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects. Antimicrob. Agents Chemother. 44: 2052-2060 [Abstract] [Full Text]  
  • McDowell, J. A., Lou, Y., Symonds, W. S., Stein, D. S. (2000). Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults. Antimicrob. Agents Chemother. 44: 2061-2067 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»